Arylamine N-acetyltransferase 2 gene polymorphism in an Algerian population

References

• Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, et al. 2013. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 69:1091–1101.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21:263–265.
   PubMed Web of Science ®Google Scholar
• Chamorro JG, Castagnino JP, Musella RM, Frías A, Aranda FM, de Larrañaga GF. 2012. The distribution of allelic and genotypic frequencies of N-Acetyltransferase-2 variants in an Argentine population. J Infect Dev Ctries 6:671–674.
   PubMed Web of Science ®Google Scholar
• Dandara C, Masimirembwa CM, Magimba A, Kaaya S, Sayi J, Sommers DK, Snyman JR, Hasler JA. 2003. Arylamine N-acetyltransferase (NAT2) genotypes in Africans: the identification of a new allele with nucleotide changes 481C > T and 590G > A. Pharmacogenetics 13:55–58.
   PubMedGoogle Scholar
• Data WHO WLC-i-P: Global tuberculosis report. 2013. In Book Global tuberculosis report. 2013. Edited by Global tuberculosis report 2013. Switzerland: World Health Organization (WHO).
   Google Scholar
• Deitz AC, Rothman N, Rebbeck TR, Hayes RB, Chow WH. 2004. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 13:1543–1546.
   PubMed Web of Science ®Google Scholar
• Deloménie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. 1996. Genotyping of the polymorphic N-acetyltransferase(NAT*2)gene locus in two native African populations. Pharmacogenetics 6:177–185.
   PubMedGoogle Scholar
• Djordjevic N, Carrillo JA, Ueda N, Gervasini G, Fukasawa T, Suda A, Jankovic S, Aklillu E. 2011. N-Acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a White population. J Clin Pharmacol 51:994–1003.
   PubMed Web of Science ®Google Scholar
• Djordjevic N, Carrillo JA, Roh HK, Karlsson S, Ueda N, Bertilsson L, Aklillu E. 2012. Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. J Clin Pharmacol 52:1527–1534.
   PubMed Web of Science ®Google Scholar
• Doll MA, Hein DW. 2001. Comprehensive human NAT2 genotype method using single nucleotide polymorphism-specific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 288:106–108.
   PubMed Web of Science ®Google Scholar
• Du H, Chen X, Fang Y, Yan O, Xu H, Li L, Li W. 2013. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep 5:3591–3596.
   Web of Science ®Google Scholar
• Evans DA. 1986. Ethnic differences in reactions to drugs and xenobiotics. Acetylation. Prog. Clin. Biol. Res 214:209–242.
   PubMedGoogle Scholar
• Furet Y, Bechtel Y, Le Guellec C, Bechtel PR, Autret-Leca A. 2002. Clinical relevance of N-acetyltransferase type 2 (NAT2) genetic polymorphism. Therapy 57:427–431.
   Google Scholar
• Guaoua LS, Ratbi I, Laarabi FZ, Elalaoui SC, CherkaouiJaouad I, Barkat A, Sefiani A. 2014. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population. BMC Genetics 15:1–6.
   PubMed Web of Science ®Google Scholar
• Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, Ramegowda PH. 2013. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J. GastroenterolHepatol 8:1368–1374.
   Google Scholar
• Hallassa SA. 2012. Manuel de la lutte antituberculeuse. Ministère de la santé, de la population et de la réforme hospitalière (Algeria). Algérie: Edition & Publications – ANDS.
   Google Scholar
• Hamdy S, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi NE, Ahmed MS. 2003. Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population. Br J Clin Pharmacol 55:560–569.
   PubMed Web of Science ®Google Scholar
• Hein DW, Doll MA, Fretland AJ, Leff MA, Webb J, Xiao GH, Devanaboyina US, et al. 2000. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29–42.
   PubMed Web of Science ®Google Scholar
• Hein DW. 2009. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol 5:353–366.
   PubMed Web of Science ®Google Scholar
• Huang YS. 2014. Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc 77:169–173.
   PubMed Web of Science ®Google Scholar
• Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ben Ahmed S, Chouchane L. 2008. Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) Polymorphisms in Breast Carcinoma. BMC Cancer 8:1–12.
   PubMed Web of Science ®Google Scholar
• Ladero JM. 2008. Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs. Curr Drug Metab 6:532–537.
   Web of Science ®Google Scholar
• Lima R, Teixeira R, Morato RG, Cabello PH, Muniz LM, Rezende Moreira AS, Kritski AL, Mello FC. 2011. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz, Rio de Janeiro 106:716–724.
   PubMed Web of Science ®Google Scholar
• Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215.
   PubMed Web of Science ®Google Scholar
• Mushiroda T, Yanai H, Yoshiyama T, Sasaki Y, Okumura M, Ogata H, Tokunaga K. 2016. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Hum Genome Var 3:16014.
   PubMedGoogle Scholar
• Omar A, Michio M, Yamazaki A, Shibata H, Ofori MF, Akanmori BD, Shuaibu MN. 2012. Toll-like receptor 9 (TLR9) polymorphism associated with symptomatic malaria: a cohort study. Malaria J 11:168.
   PubMed Web of Science ®Google Scholar
• Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R. 2008. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 9:21–21.
   PubMed Web of Science ®Google Scholar
• Stephens M, Donnelly P. 2003. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162–1169.
   PubMed Web of Science ®Google Scholar
• Singh M, Gupta VH, Amarapurkar DN, Singh M, Gupta VH, Amarapurkar DN, Joshi JM, et al. 2014. Association of genetic variants with anti-tuberculosis drug induced hepatotoxicity: A high resolution melting analysis. Infect Genet Evol 14:30–36.
   Google Scholar
• Sistanizad M, Azizi E, Khalili H, Hajiabdolbaghid M, Gholamic K, Mahjube R. 2011. Antituberculosis drug-induced hepatotoxicity in iranian tuberculosis patients: role of isoniazid metabolic polymorphism. Iran J Pharm Res 3:633–639.
   Google Scholar
• Tanira MO, Simsek M, Al Balushi K, Al Lawatia K, Al Barawani H, Bayoumi RA. 2003. Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis. J SciRes Med Sci 5:9–14.
   PubMedGoogle Scholar
• Touré A, Diop C, Cabral M, Fall M, Lhermitte M, Diouf A, Broly F, Allorge D. 2012. Study of NAT2 genetic polymorphism in West African subjects: example of an healthy non-smoker Senegalese population. Mol Biol Rep 39:10489–10496.
   PubMed Web of Science ®Google Scholar
• Umamaheswaran G, Krishna Kumar D, Adithan C. 2014. Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters – a review with Indian perspective. Indian J Med Res 139:27–65.
   PubMed Web of Science ®Google Scholar
• Vuilleumier N, Rossier MF, Chiappe A. 2006. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62:423–429.
   PubMedGoogle Scholar
• Wattanapokayakit S, Mushiroda T, Yanai H, Wichukchinda N, Chuchottawon C, Nedsuwan S, Rojanawiwat A, et al. 2016. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int J Tuberc Lung Dis 20:1364–1369.
   PubMed Web of Science ®Google Scholar
• Woodward KN, Timbrell JA. 1984. Acetylhydrazine hepatotoxicity: the role of covalent binding. Toxicology 30:65–74.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, Wang Q, et al. 2014. The Incidence of Liver Injury in Uyghur Patients Treated for TB in Xinjiang Uyghur Autonomous Region, China, and Its Association with Hepatic Enzyme Polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1. PLoS One 9:1–8.
   Web of Science ®Google Scholar
• Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, et al. 2011. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients . PLoS One 6:e27810.
   PubMed Web of Science ®Google Scholar
• Yuliwulandari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I, Kristin E, et al. 2016. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet 61:533–537.
   PubMed Web of Science ®Google Scholar
• Zabost A, BrzeziNska S, KoziNska M, Zabost A, Blachino M, Jagodzinski J. 2013. Correlation of N-Acetyltransferase 2 Genotype withIsoniazid Acetylation in Polish Tuberculosis Patients. BioMed Res 2013:1–5.
   Web of Science ®Google Scholar